GSK Spreads Smoking-Cessation Aids To Countries Serious About Quitting
This article was originally published in The Tan Sheet
GlaxoSmithKline plans to introduce its smoking-cessation products to 800 million people over the next four years in countries working to reduce smoking among their populations
You may also be interested in...
The likelihood of Congress handing FDA responsibility for regulating tobacco has ignited debate over whether the new purview would distract an already struggling agency from its mission
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
DuPont says it and P&G “have conducted extensive research on human commensals bacteria to help address metabolic health issues in humans.” The partnership "will help us further advance our probiotic innovation via a next generation solution that will prove beneficial to the health and well-being of consumers around the world,” says Paul Gama, P&G personal health care president.